Baxfendy Hypertension Treatment: FDA Approves F...

By HEOR Staff Writer

May 22, 2026

Baxfendy hypertension treatment received US Food and Drug Administration approval as the first aldosterone synthase inhibitor for adults with hypertension not adequately controlled on other antihypertensive medications. AstraZeneca’s Baxfendy (bax...
TrumpRx.gov Expansion: Enhancing Medication Price Transparency and Competition
Substandard Medicines in South Africa: Regulatory Challenges and Economic Imp...
First-in-Human Trials: Foundations and Market Implications in Health Economics
Transforming Healthcare Value: Strategic Purchasing in South Africa
Learning from Global Best Practices in Healthcare Pricing Regulation
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
Portugal’s MAP02 Medication Adherence Initiative: Enhancing Therapeutic...
Healthcare Innovation Trends: Insights from the Healthcare Economics Conferen...
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvan...
Pharmaceutical Onshoring Agreements: Navigating Tariff Relief and National Se...
Core Recommendations for Equitable Digital Medicine Access
Advancements in Intranasal Drug Delivery: Hovione and IDC Launch Commercial P...